CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Breast Cancer Heterogeneity and Response to Novel Therapeutics
Authors
Mariona Baliu-Piqué
Alberto Ocaña
Atanasio Pandiella
Publication date
25 February 2021
Publisher
'MDPI AG'
Doi
Cite
Abstract
© 2020 by the authors.Targeted cancer therapies against oncogenic drivers are actively being developed and tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation is present in most tumoral cells. Therefore, highly heterogeneous tumors may be refractory to these therapies. This makes tumor heterogeneity a major challenge in cancer therapy. Although heterogeneity has traditionally been attributed to genetic diversity within cancer cell populations, it is now widely recognized that human cancers are heterogeneous in almost all distinguishable phenotypic characteristics. Understanding the genetic variability and also the non-genetic influences of tumor heterogeneity will provide novel insights into how to reverse therapeutic resistance and improve cancer therapy.This work has been supported by CRIS Cancer Foundation, Instituto de Salud Carlos III (PI19/00808), ACEPAIN, ALMOM, Diputación de Albacete and CIBERONC
Similar works
Full text
Available Versions
Digital.CSIC
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:digital.csic.es:10261/2306...
Last time updated on 03/03/2021